Citadel Advisors
WHWK

Citadel Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Citadel Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,600
Closed -$4.63K – 15723
2025
Q1 		$4.63K Sell
2,600
-12,400
-83% -$32.4K ﹤0.01% 13876
2024
Q4 		$47.3K Sell
15,000
-8,800
-37% -$19.9K ﹤0.01% 12452
2024
Q3 		$49K Buy
23,800
+14,400
+153% +$23.3K ﹤0.01% 11939
2024
Q2 		$13.7K Buy
9,400
+4,500
+92% +$8.34K ﹤0.01% 12927
2024
Q1 		$11.5K Sell
4,900
-6,500
-57% -$12.5K ﹤0.01% 13409
2023
Q4 		$23K Buy
11,400
+1,400
+14% +$5.87K ﹤0.01% 12504
2023
Q3 		$48.4K Sell
10,000
-31,500
-76% -$183K ﹤0.01% 11788
2023
Q2 		$284K Buy
41,500
+40,300
+3,358% +$313K ﹤0.01% 9175
2023
Q1 		$8.69K Sell
1,200
-71,100
-98% -$760K ﹤0.01% 13641
2022
Q4 		$928K Sell
72,300
-61,600
-46% -$804K ﹤0.01% 6960
2022
Q3 		$1.89M Sell
133,900
-12,200
-8% -$160K ﹤0.01% 5694
2022
Q2 		$1.8M Buy
146,100
+91,400
+167% +$1.36M ﹤0.01% 5761
2022
Q1 		$928K Buy
+54,700
New +$1.05M ﹤0.01% 7880

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors's WHWK Position: Q1 2026 in Review

Citadel Advisors reduced its Whitehawk Therapeutics (WHWK) stake by 7.2% in Q1 2026, selling an estimated $22.2K and leaving 91,852 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #10357.

Citadel Advisors first reported a position in WHWK in Q3 2019 and has held it in 25 quarters since. The position peaked at $5.57M in Q4 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Citadel Advisors held 91,852 shares of Whitehawk Therapeutics worth $317K as of Q1 2026.
  • Citadel Advisors sold 7,098 Whitehawk Therapeutics shares in Q1 2026, an estimated $22.2K.
  • Whitehawk Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10357 holding.
  • Citadel Advisors first reported a position in Whitehawk Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Whitehawk Therapeutics position peaked at $5.57M in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.